Mixed Tumour Groups

Currently Recruiting


CA009-002

A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone
and in Combination With Nivolumab (BMS-936558, Anti PD-1 Monoclonal Antibody) in Advanced Solid Tumours

Sponsor: Bristol-Myers Squibb

The purpose of this study is to evaluate the safety, tolerability pharmacokinetics, pharmacodynamics, immunogenicity and preliminary
 anti-tumor activity of BMS-986156 when administered alone and in combination with nivolumab in subjects with advanced solid tumours

More info: Click Here
 
Status: Recruiting
 
Contact: Jo Jackson
______________________________________________________________________________________________________________________________________________________________________________________________________________________________________

CA017-003

A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both
Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumours

Sponsor: Bristol-Myers Squibb

The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab
and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced or have spread. Pharmacokinetics and
pharmacodynamics of BMS-986205 when combined with Nivolumab and in combination with Nivolumab and Ipilimumab in this patient
population will also be assessed.

Types of Cancers: Advanced Cancer, Melanoma, Non-Small Cell Lung Cancer

More info:  Click Here
 
Status: Recruiting
 
Contact: Medhia Survery


CLAG525X2101

A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination
With PDR001 Administered to Patients With Advanced Malignancies

Sponsor: Novartis Pharmaceuticals

This study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525
as a single agent and in combination with PDR001 to adult patients with solid tumors. The study consists of a dose escalation phase (Ib) to
determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) for LAG525 as a single agent and in combination with PDR001,
and a dose expansion phase (II) which will characterize treatment of LAG525 as a single agent and in combination with PDR001 at the MTD or RP2D.

Types of Cancers: Renal, Lung, Melanoma

More info: Click Here
 
Status: Recruiting
 
Contact: Sophia Chan












Comments